Lectins have also been developed for the detection of specific aberrant and cancer-associated glycostructures to assist diagnosis, prognosis based on the assessment of patient serum glycoproteins using lectins, such as Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) (31), Galectin-8 (32), and Galectin-3 (33). Here, LGALS3 is linked to cancer.